Loading...
XLON
BPCR
Market cap1.07bUSD
Jul 10, Last price  
0.96USD
1D
0.63%
1Q
2.13%
IPO
-99.07%
Name

BioPharma Credit PLC

Chart & Performance

D1W1MN
XLON:BPCR chart
P/E
8.29
P/S
7.68
EPS
0.12
Div Yield, %
10.11%
Shrs. gr., 5y
-3.67%
Rev. gr., 5y
7.88%
Revenues
140m
+12.67%
33,648,86378,721,000124,119,00095,959,000126,394,000213,771,000159,682,000124,457,000140,231,000
Net income
130m
+6.31%
27,163,71970,146,000122,328,00089,136,00084,959,000182,311,000108,450,000122,178,000129,887,000
CFO
91m
-18.60%
23,068,29067,138,000131,520,00058,072,00096,436,000184,277,000123,182,000111,912,00091,095,000
Dividend
Sep 25, 20250.0325 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

As an investment trust, BioPharma Credit PLC primarily allocates its portfolio to debt assets that generate interest. The security for these investments is provided by royalty payments or other cash flows stemming from the sales of officially approved life sciences products. The firm was established in 2016 and maintains its headquarters in Exeter, United Kingdom.
IPO date
Mar 27, 2017
Employees
0
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT